argenx SE Files Form 6-K for Q1 2025 Reporting
Ticker: ARGX · Form: 6-K · Filed: May 8, 2025 · CIK: 1697862
Sentiment: neutral
Topics: sec-filing, 6-K, biotech
TL;DR
ARGENX filed a 6-K for Q1 2025. Keep an eye on their pipeline updates.
AI Summary
On May 8, 2025, argenx SE filed a Form 6-K, reporting information for the period ending March 31, 2025. The filing includes details about the company's operations and financial status as a foreign private issuer. argenx SE is a biopharmaceutical company focused on developing treatments for autoimmune diseases and cancer.
Why It Matters
This filing provides investors with updated information on argenx SE's performance and regulatory disclosures for the first quarter of 2025, crucial for understanding the company's ongoing development and financial health.
Risk Assessment
Risk Level: low — This is a routine periodic filing (6-K) that provides an update on the company's status and does not contain significant new material events or financial results that would inherently increase risk.
Key Players & Entities
- argenx SE (company) — Registrant
- 001-38097 (company) — Commission File Number
- 20250331 (date) — Conformed Period of Report
- 20250508 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed by argenx SE for the month of May 2025, reporting on the period ending March 31, 2025.
What is argenx SE's primary business?
argenx SE is a biopharmaceutical company, as indicated by its Standard Industrial Classification code for Biological Products (NO DIAGNOSTIC SUBSTANCES).
When was argenx SE's name last changed?
The company's former name was argenx N.V., and the date of the name change was February 10, 2017.
Where is argenx SE's principal executive office located?
The principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
Does argenx SE file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files or will file annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 8, 2025 regarding ARGENX SE (ARGX).